161/222US=92 / Biol/Mol
Oleinick NL, Morris RL, Nieminem AL. Recent and developing cancer therapies: photodynamic therapy-induced apoptosis. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 557-78. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

TERAPIA FOTODINAMICA; FOTOSSENSIBILIZADOR; MITOCONDRIA LISOSSOMO; RETICULO ENDOPLASMATICO; APOPTOSE


162/222US=92 / Biol/Mol
Fulda S, Debatin KM. Recent and developing cancer therapies: modulation of TRAIL signaling for cancer therapy. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 579-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

APOPTOSE; TRAIL; DROGAS; TERAPIA DO CANCER


163/222US=95 / Biol/Mol
Zhang L, Fang B. Gene therapy approaches: oncogenes, tumor suppressor genes and apoptosis-inducing genes utilized in cancer gene therapy. In: Hunt KK, Vorburger AS, Swisher SG. Gene therapy for cancer. New Jersey: Humana Press, 2007. p. 173-84. (Cancer Drug Discovery and Development) ISBN 978-0-470-19756-1.

CANCER; TERAPIA GENETICA; TERAPIA DE GENES; ONCOGENES; GENES SUPRESSORES DE TUMORES; APOPTOSE; ADENOVIRUS


164/222US=10 / Biol/Mol
Pelengaris S, Khan M. Apoptosis. In: ___. The molecular biology of cancer. Oxford: Blackwell, 2006. p. 251-78. ISBN 978-1-4051-1814-9.

FORMACAO DE CANCER; APOPTOSE CONTRA NECROSE; SUPRESSOR TUMORAL P53; MORTE CELULAR


165/222US=17 / Biol/Mol
Kiaris H. Basic aspects: the cell's life and death: cell cycle, senescence and apoptosis. In: ___. Understanding carcinogenesis: an introduction to the molecular basis of cancer. Weinheim: Wiley-VCH, 2006. p. 5-13. ISBN 978-3-527-31486-7.

CICLO CELULAR; SENESCENCIA; APOPTOSE; MORTE CELULAR; APOPTOSE CONTRA NECROSE


166/222US=2 / Biol/Mol
Gülow K, Kaminski M, Krammer PH. Death receptor: the role of CD95/CD95 ligand signaling in apoptosis and cancer. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 3-30. ISBN 978-3-527-31237-5.

RECEPTOR MORTE; SISTEMA CD95; SISTEMA CD95L; SINALIZACAO DA APOPTOSE; CANCER; MAQUINARIA APOPTOTICA; VIA INTRINSECA; VIA EXTRINSECA; MITOCONDRIAS; MECANISMOS DE RESISTENCIA; ANGIOGENESE


167/222US=2 / Biol/Mol
Walczak H, Koschny R, Willen D, Schader MB, Sykora J, Ganten TM, Haas TL. Death receptor: the TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological function. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 31-92. ISBN 978-3-527-31237-5.

RECEPTOR MORTE; SISTEMA DE RECEPTOR-LIGANTE TRAIL; BIOQUIMICA DA INDUCAO DE APOPTOSE; POTENCIAL TERAPEUTICO; CANCER. TERAPIA; FUNCAO FISIOLOGICA; ATIVACAO DA CASPASE; FAMILIA BCL-2; UBIQUITINA; TERAPIA GENETICA; INFECCAO VIRAL; IMUNOPATOLOGIAS; DOENCAS AUTO-IMUNES; TRANSPLANTE ALOGENICO DE CELULAS-TRONCO HEMATOPOETICAS


168/222US=2 / Biol/Mol
Wajant H. Death receptor: mechanisms of tumor necrosis factor-induced cell death. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 93-119. ISBN 978-3-527-31237-5.

RECEPTOR DE MORTE; MORTE CELULAR; FATOR DE NECROSE TUMORAL; APOPTOSE; CANCER. TERAPIA


169/222US=2 / Biol/Mol
Micheau O. Death receptor: cellular FLICE-inhibitory protein: an update. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 120-56. ISBN 978-3-527-31237-5.

CANCER; RECEPTOR MORTE; PROTEINA INIBITORIA DA FLICE; GENE FLIP


170/222US=2 / Biol/Mol
Mehlen P, Lourenço FC. Death receptor: dependence receptors and apoptosis. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 157-82. ISBN 978-3-527-31237-5.

RECEPTOR DE MORTE; RECEPTORES DE DEPENDENCIA; APOPTOSE; INTEGRINA; TIROSINA QUINASE


171/222US=2 / Biol/Mol
Saelens X, Festjens N, Walle LV, Vandenabeele P. Mitochondria: role of mitochondrial proteins in apoptosis. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 183-221. ISBN 978-3-527-31237-5.

APOPTOSE; PAPEL DAS PROTEINAS MITOCONDRIAIS; FAMILIA BCL-2; PERMEABILIZACAO DA MEMBRANA MITOCONDRIAL; MUTACOES APOPTOTICAS; CITOCROMO C


172/222US=2 / Biol/Mol
Suzuki Y, Takahashi R. Mitochondria: omi/HtrA2: a mitochondrial serine protease regulating cellular life and death. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 222-32. ISBN 978-3-527-31237-5.

MITOCONDRIAS; OMI/HTRA2; SERINA PROTEASE MITOCONDRIAL; MORTE CELULAR


173/222US=2 / Biol/Mol
Vahsen N, Kroemer G. Mitochondria: apoptosis-inducing factor. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 233-55. ISBN 978-3-527-31237-5.

MITOCONDRIAS; FATOR DE INDUCAO DE APOPTOSE; ISOFORMES


174/222US=2 / Biol/Mol
Adrain C, Martin SJ. Effector systems: caspases: agents of defense and destruction. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 259-81. ISBN 978-3-527-31237-5.

SISTEMAS EFETORES; CASPASES; APOPTOSE


175/222US=2 / Biol/Mol
Cain K. Effector systems: the role of the apoptosome and cancer therapy. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 282-313. ISBN 978-3-527-31237-5.

SISTEMAS EFETORES; TERAPIA APOPTOSSOMO; CANCER; CITOCROMO C; CASPASE


176/222US=2 / Biol/Mol
Naik E, Strasser A. Bcl-2 family: the role of the Bcl-2 protein family in tumorigenesis and cancer therapy. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 317-45. ISBN 978-3-527-31237-5.

FAMILIA BCL-2; TUMORIGENESE; CANCER. TERAPIA; MORTE CELULAR; APOPTOSE


177/222US=2 / Biol/Mol
Dempsey CE, Roberts DL, Dive C. Bcl-2 family: bax, bak and bid: key mediators of apoptosis. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 346-78. ISBN 978-3-527-31237-5.

FAMILIA BCL-2; BAX; BAK; BID; MEDIADORES DE APOPTOSE; VIAS MITOCONDRIAIS; CANCER


178/222US=2 / Biol/Mol
Erlacher M, Michalak EM, Strasser A, Villunger A. Bcl-2 family: the BH3-only proteins puma and noxa: two brothers in arms. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 379-402. ISBN 978-3-527-31237-5.

FAMILIA BCL-2; PROTEINAS BH3; PUMA; NOXA; REGULACAO DA P53; MORTE CELULAR


179/222US=2 / Biol/Mol
Holcik M. IAPs: inhibitor of apoptosis proteins. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 403-26. ISBN 978-3-527-31237-5.

IAPS; INIBIDORES DE PROTEINAS DE APOPTOSE


180/222US=2 / Biol/Mol
Altieri DC. IAPs: targeting the survivin pathway for rational cancer therapy. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 427-42. ISBN 978-3-527-31237-5.

IAPS; SURVIVINA; INIBIDOR DE PROTEINA A APOPTOSE


Primeira | Anterior | Próxima | Última